Pham Quang X, serving as both Chairman and Chief Executive Officer of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), finalized the disposition of 7,400 shares of the company's common equity on June 29, 2026. The transaction generated total proceeds amounting to $22,422. Execution of the sale occurred at a weighted average price point of $3.03 per share, with specific fill prices varying between $3.00 and $3.13. This divestment was processed under the parameters of a Rule 10b5-1 trading arrangement, a pre-arranged plan adopted by Mr. Pham on September 25, 2025, designed to facilitate stock transactions in compliance with securities regulations.
Following the completion of this transaction, Mr. Pham's direct ownership position in Cadrenal Therapeutics stands at 98,589 shares. Beyond these direct holdings, he maintains an indirect stake of 200,000 shares held within The PVBQ Living Trust. As the Trustee of this entity, Mr. Pham exercises sole voting and dispositive power over the assets, with his child designated as the sole beneficiary. The sale activity takes place while the company's equity is trading at $3.17, a level that reflects a substantial 74% decline over the past year from its 52-week high of $14.64. Market data indicates heightened volatility for the stock, characterized by a beta coefficient of 1.61. Despite the price compression, valuation analysis from InvestingPro suggests the current share price may be below intrinsic value, estimating a fair value of $3.77. The company's liquidity position remains intact, supported by a current ratio of 2.68.
In parallel with executive share activity, Cadrenal Therapeutics has advanced several corporate and clinical milestones. The company announced a private placement agreement with a healthcare-focused institutional investor, a transaction expected to generate $3 million in gross proceeds. Under the terms of this agreement, Cadrenal will issue 960,000 shares of common stock or pre-funded warrants. The deal also includes an additional series of warrants, specifically series C-1 and series C-2, which provide the option to purchase up to 960,000 additional shares.
On the clinical front, data supporting the company's drug candidate CAD-1005 has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis. This presentation will detail outcomes from a Phase 2 trial evaluating the treatment in patients suffering from Heparin-Induced Thrombocytopenia. Furthermore, the company has secured guidance from the U.S. Food and Drug Administration for a pivotal Phase 3 trial of CAD-1005. This trial aims to evaluate the treatment's efficacy in the same patient population and is intended to support a projected New Drug Application submission in 2029.
Additionally, Cadrenal Therapeutics plans to submit a request for Rare Pediatric Disease Designation to the FDA for tecarfarin. This designation aims to facilitate the treatment of pediatric patients diagnosed with Kawasaki disease. The convergence of these clinical developments and capital raising efforts underscores the company's active phase of operational expansion despite the recent volatility in its equity price.